Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
anti-VISTA x MSLN bispecific antibody-interferon beta mutein fusion protein
- Development stage
- Preclinical
- Lead developer
- Seoul National University
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Cytokines & Interferons → Recombinant Proteins and Enzymes
01
Overview
The anti-VISTA x MSLN bispecific antibody-interferon beta mutein fusion protein is a trispecific immunocytokine developed for the treatment of epithelioid malignant pleural mesothelioma (MPM). It consists of a bispecific antibody targeting the immune checkpoint V-domain Ig suppressor of T cell activation (VISTA) and the tumor differentiation antigen Mesothelin (MSLN), fused to a stabilized interferon-beta (IFN-β) mutein containing R27T and C17S mutations. This fusion protein is designed to leverage the co-expression of VISTA and MSLN in epithelioid MPM to localize IFN-β activity to the tumor microenvironment, thereby enhancing anti-tumor efficacy while minimizing systemic toxicity. The drug acts through multiple mechanisms, including direct cytotoxicity from IFN-β, antibody-dependent cell cytotoxicity (ADCC) mediated by the antibody component, and the activation of immune cells via VISTA blockade and IFN-β signaling.
- Other names
- VISTA x MSLN BsAb-IFN-β mutein fusion proteinVISTA-MSLN-IFNβ trispecific immunocytokine
02
Targets
IFNAR (Immune system modulation via type I interferon receptor)IFNAR2 (Interferon alpha/beta receptor subunit 2)MesothelinVISTAIFNAR1 (Interferon alpha/beta receptor 1)
Beyond the preview
Go deeper on anti-VISTA x MSLN bispecific antibody-interferon beta mutein fusion protein.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on anti-VISTA x MSLN bispecific antibody-interferon beta mutein fusion protein.